Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis

Clinical Remission of Primary Cutaneous Marginal Zone B-Cell Lymphoma in a Patient With Crohn’s Disease After Helicobacter pylori Quadruple Therapy and Vedolizumab

“…A previous study cited a therapeutic role for vedolizumab in a case of oral idiopathic lymphoplasmacellular mucositis-dermatitis in a patient with ulcerative colitis. 17 Local treatment of the affected lower lip was enhanced with systemic vedolizumab; the authors theorized that this effect was due to plasma cells expressing a₄b₇ and the MAdCAM-1 expressed in oral mucosa, thus, plasma cells of the oral mucosa inhibited by vedolizumab. This theory could prove to be relevant in our patient's case, owning that the biopsy's tumefactive nodular configuration was heterogenous with admixed plasma cells.…”